| Name | G1/S-specific cyclin-E2 | ||
| UniProt ID | CCNE2_HUMAN | ||
| Gene Name | CCNE2 | ||
| Gene ID | 9134 | ||
| Synonyms |
CCNE2, CYCE2
|
||
| Sequence |
MSRRSSRLQAKQQPQPSQTESPQEAQIIQAKKRKTTQDVKKRREEVTKKHQYEIRNCWPP
VLSGGISPCIIIETPHKEIGTSDFSRFTNYRFKNLFINPSPLPDLSWGCSKEVWLNMLKK ESRYVHDKHFEVLHSDLEPQMRSILLDWLLEVCEVYTLHRETFYLAQDFFDRFMLTQKDI NKNMLQLIGITSLFIASKLEEIYAPKLQEFAYVTDGACSEEDILRMELIILKALKWELCP VTIISWLNLFLQVDALKDAPKVLLPQYSQETFIQIAQLLDLCILAIDSLEFQYRILTAAA LCHFTSIEVVKKASGLEWDSISECVDWMVPFVNVVKSTSPVKLKTFKKIPMEDRHNIQTH TNYLAMLEEVNYINTFRKGGQLSPVCNGGIMTPPKSTEKPPGKH |
||
| Pathway Map | MAP LINK | ||
| KEGG ID | hsa9134 | ||
| TTD ID | T19027 | ||
| Pfam | PF00134; PF02984 | ||
| Pair Name | Luteolin, Tamoxifen | |||
| Phytochemical | Luteolin | |||
| Drug | Tamoxifen | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Regulate Info | Down-regulation | G1/S-specific cyclin-E2 | Expression | |
| Result | The results of this study suggest that luteolin can be used as a chemosensitiser to target the expression level of CCNE2 and that it could be a novel strategy to overcome TAM resistance in breast cancer patients. | |||
